Skip to main content

Table 1 Baseline characteristics of patients with NAFLD participated in our study before interventiona

From: Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

VariablesPlacebo groupCurcumin groupP value
Age (year)10.9 ± 45.1311.5 ± 46.190.473
Sex (male, n,(%))14 (51.9%)13 (48.1%)0.407
Physical Activity (MET.h.d)4.63 ± 32.033.65 ± 32.690.592
Smoking  0.167
 Yes (Smoker or Ex-smoker)4 (17%)1 (4%) 
 No (Never smoked)19 (83%)26 (96%) 
Weight (kilogram)89.22 ± 13.0585.02 ± 11.160.225
BMI (kg/m2)32.38 ± 5.0232.30 ± 4.550.956
Waist circumference (cm)103.28 ± 8.83102.19 ± 8.780.948
Total energy (kcal)2323.01 ± 540.592355.41 ± 703.690.858
hs-CRP (ng/dL)6705.05 ± 4797.95647.15 ± 3858.40.412
TNF-α (pg/mL)18.63 ± 2.219.34 ± 5.40.610
NF-κB2.13 ± 0.922.07 ± 1.030.842
Fibrosis grade (kPa)6.52 ± 2.386.98 ± 2.420.132
Steatosis grade (db/m)315.18 ± 35.69298.35 ± 29.50.218
  1. aData are presented as mean ± SD except for gender, which is reported as number (%)
  2. NAFLD none-alcoholic Fatty Liver Disease, BMI body mass index, TNF tumor necrosis factor, NF-kB Nuclear factor kappa B, hs-CRP high sensitive C reactive protein